Exploring the Strategic Investment Decisions of a Renowned Value Investor Jeff Auxier (Trades, Portfolio) recently submitted the 13F filing for the fourth quar

VANCOUVER, BC / ACCESS Newswire / February 13, 2026 / (TSXV:OGN)(OTCQB:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") announces that, as part of the Company's annual share-based compensation program, the Board of Directors have authorized a grant of 132,000 Restricted Share Units (RSUs), 29,000 Deferred Share Units (DSUs), and 618,000 incentive Stock Options to directors, officers, employees, and consultants. The grant has been authorized pursuant to the Company's Omnibus Equity Incentive Compensation Plan that was approved by shareholders June 27, 2025.

Organon reported disappointing 2025 results, with revenues down 3% and no growth expected in 2026. OGN faces potentially terminal declines in established brands, flat biosimilar growth, and underwhelming Women's Health performance, all compounded by ~$8bn in net debt. The dividend was slashed last year to $0.02/quarter, a yield of now ~1%, with capital allocation constrained by high-interest expenses and limited M&A capacity.

Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Organon & Co. (OGN) Q4 2025 Earnings Call Transcript

Organon (OGN) came out with quarterly earnings of $0.63 per share, missing the Zacks Consensus Estimate of $0.73 per share. This compares to earnings of $0.9 per share a year ago.

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces Q4 2025 and Full Year 2025 earnings results, ending December 31, 2025.

Shares of Organon and Co. (NYSE: OGN - Get Free Report) have been given an average rating of "Reduce" by the seven brokerages that are covering the stock, Marketbeat.com reports. Five investment analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and one has issued a strong buy recommendation on

Organon (OGN) concluded the recent trading session at $8.2, signifying a -3.98% move from its prior day's close.

OGN completes JADA System divestiture to Laborie for up to $465M, bolstering its balance sheet and backing debt reduction to fund women's health growth.